Jarrod Niebloom, JD
Chairman
Mr. Niebloom was a faculty member at the Harvard Law School, and has advised global corporations, federal and state government officials and other high-profile clients on a range of constitutional and complex legal matters, including antitrust, various aspects of federal justiciability doctrine, preemption and a host of federal statutory and administrative issues. He has worked with litigants and counsel in cases before the U.S. Supreme Court and has authored the forthcoming law treatise, Constitutional Principles, Antitrust Theory. Mr. Niebloom earned a JD from Harvard Law School, and a BA in Quantitative Economics and Political Theory from Tufts University.
Martin Madaus, PhD
Independent Director
Dr. Madaus is an Operating Executive at the Carlyle Group. Dr. Madaus has previously served as CEO of Roche Diagnostics (North America), Chairman and CEO of Ortho Clinical Diagnostics, President, Chairman and CEO of Millipore Corporation (acquired by Merck) and Lead Director of Quanterix. He earned a Doctor of Veterinary Medicine from the University of Munich, Germany, and a PhD in Veterinary Medicine from the Veterinary University of Hannover, Germany.
Susan Volkert, JD, LLM
Independent Director
Ms. Volkert is currently a litigation Partner at DeCoitis, FitzPatrick & Cole, LLP, and previously served as Chief Compliance Officer, Vice President and Deputy General Counsel of Hoescht Celanese (Sanofi Aventis). Ms. Volkert served as the Deputy Chief of the Torts and Commercial Litigation Branches of the U.S. Department of Justice in Washington, D.C., and as the Deputy Chief of the Civil Division of the the U.S. Attorney’s Office for the District of New Jersey. Ms. Volkert is a graduate of UPenn and the University of Toledo Law School and holds an LLM in Health Law from Seton Hall University School of Law.
Galit Frydman, DVM, ScD
Director
Dr. Frydman holds positions in the Division of Trauma, Emergency Surgery and Surgical Critical Care at the Massachusetts General Hospital and in the Center for Biomedical Engineering at the Massachusetts Institute of Technology, where she specializes in coagulopathies and immunothrombosis. Dr. Frydman has completed several fellowships at MIT, HMS and MGH, where she developed Coagulo’s platform technology. She has published numerous papers and book chapters on coagulation, platelet physiology, immunothrombosis and stem cell biology. Dr. Frydman earned a ScD in Biological Engineering from MIT, a DVM from the University of Florida, and a BS in Biology from Carnegie Mellon University.
Hillel Bachrach, MBA
Director
Mr. Bachrach is the Managing Partner and Executive Chairman of 20/20 HealthCare Partners LLC. Previously, Mr. Bachrach served as the Executive Chairman of Viztek (acquired by Konica Minolta in 2015), President of Odin Medical Technologies (acquired by Medtronic in 2006), President and CEO of OREX Computed Radiography (acquired by Kodak in 2005), helped found UltraSPECT, co-founded MSq (now Alma Lasers, acquired by Fosun Pharma) and co-founded and served as the Executive Vice President and Vice Chairman of ESC Medical Systems (public in 1996, now Lumenis). Mr. Bachrach holds an MBA from Northwestern University’s J.L. Kellogg Graduate School of Management and a BS in Electronic Engineering from the Technion Israeli Institute of Technology.
Derek Lee
Director
Mr. Lee is the founder and managing director of DHL Ventures LLC, and senior advisor at Athyrium Capital Management LP. Mr. Lee has co-founded, invested in and advised companies across biotechnology, medical devices and healthcare services, and previously served as founder, CFO and CDO of Talaris Advisors, a senior analyst at Burrage Capital, a principal at SV Life Sciences, and held investment banking positions in the Global Healthcare Group at UBS Warburg and in the Healthcare Investment Banking Group at Salomon Smith Barney. Mr. Lee earned a BS in Finance, Accounting and Economics from Bentley University.